Interstitielle Lungenerkrankung bei systemischer Sklerose - Therapie

Literatur

• 1 Binks M, Passweg J, Furst D, McSweeney P, Sullivan K, Besenthal C. et al . Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.  Ann Rheum Dis. 2001;  60 577-584
• 2 Black C, Silman A, Herrick A, Denton C, Wilson H, Newman J. et al . Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma. Results of a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 1999;  42 299-305
• 3 Cheema G, Quismorio F. Interstitial lung disease in systemic sclerosis.  Curr Opin Pulm Med. 2001;  7 283-290
• 4 Clements P, Furst D, Wong W, Mayes M, White B, Wigley F. et al . High-dose versus low-dose D-Penicillamine in early diffuse systemic sclerosis.  Arthritis Rheum. 1999;  42 1194-1203
• 5 Ellman M, MacDonald P, Hayes A. Etanercept as treatment for diffuse scleroderma: a pilot study.  Arthritis Rheum. 2000;  43 S392
• 6 Magnussen F, Gorckenjan D, Kohler D, Matthys H, Morr H, Orthe H. et al . Leitlinien zur Sauerstofflangzeittherapie.  Pneumologie. 2001;  55 454-464
• 7 Olschewski H, Ghofrani H, Schmel T, Winkler J, Wilkens H, Hoper M. et al. and German PPH Study group . Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial.  Ann Intern Med. 2000;  132 435-443
• 8 Pope J, Bellamy N, Seibold J, Baron M, Ellman M, Carette S. et al . A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.  Arthritis Rheum. 2001;  44 1351-1358
• 9 Pritzker M, Dorman W. The use of sildenafil (Viagra) for the treatment of pulmonary hypertension associated with scleroderma.  Arthritis Rheum. 2001;  44 S131
• 10 Schnabel A, Reuter M, Gross W. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.  Arthritis Rheum. 1998;  41 1215-1220
• 11 Steen V, Lanz J, Conte C, Owens G, Medsger T A Jr. Therapy for severe interstitial lung disease in systemic sclerosis: A retrospective study.  Arthritis Rheum. 1994;  37 1290-1296
• 12 Strange C, Bolster M, Mazur J, Taylor, Gossage J, Silver R M. Hemodynamic effectors of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.  Chest. 2000;  118 1077-1082
• 13 Vallance D, Lynch J, McCune W. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.  Curr Opin Rheumatol. 1995;  7 174-182
• 14 Varai G, Earle L, Jiminez S, Steiner R, Varga J. A pilot study of intermittent introvenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.  J Rheumatol. 1998;  25 1325-1329
• 15 White B, Moore C, Wigley F, Xiao H, Wise R. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.  Ann Intern Med. 2000;  132 947-954

Korrespondenz